文献-镇痛||A型毒素的镇痛优点

文献-镇痛||A型毒可抑制用于膝中枢神经节诱导治疗法精细全球性呼吸困难症候群

A型可抑制用于膝中枢神经节诱导治疗法精细全球性呼吸困难症候群：一项随机试验性

Co背景：Co

本学术研究旨在验证可抑制通过持续性升高皮肤气压顺延膝中枢神经诱导持续性时间的举例。所写同步进行了一项随机、双盲、对照试验性，学术研究a型可抑制治疗法精细全球性呼吸困难症候群病变膝中枢神经节诱导的临床研究。

Co工具：Co

采用75 IU A型可抑制（可抑制组）和局部药（实验组），对下肢精细全球性呼吸困难症候群病变同步进行膝中枢神经节诱导。

主要结果是1个月末后诱导侧足底与对侧足底的相对低温变化。

次要结果是3个月末后的相对低温变化以及呼吸困难强度变化。

Co结果：Co

共有48名参与者（N=24/组）被随机分配。

可抑制组的相对气压增加低于实验组（分作1.0±1.3℃ vs. 0.1±0.8℃；不同：0.9℃[95%CI：0.3～1.5]；P=0.006）。

维持至术后3个月末，为1.1±0.8 ℃ vs.-0.2±1.2 ℃；P=0.009。

此外，与实验组相比，可抑制组在1个月末（分作（-2.2±1.0 vs.-1.0±1.6；P=0.003）和3个月末（分作（-2.0±1.0 vs.-0.6±1.6；P=0.003）时的呼吸困难强度显著降低。

没与可抑制药剂相关的严重过多事件。

Co结论：Co

在精细全球性呼吸困难症候群病变中，用到A型可抑制同步进行膝中枢神经节诱导可使患足气压升高3个月末，并可减轻呼吸困难。

Botulinum Toxin Type A for Lumbar Sympathetic GanglionBlock in Complex Regional Pain Syndrome: A Randomized Trial

Background: The present study was designed totest the hypothesis that botulinum toxin would prolong the duration of a lumbarsympathetic block measured through a sustained increase in skin temperature.The authors performed a randomized, double-blind, controlled trial to investigatethe clinical outcome of botulinum toxin type A for lumbar sympathetic ganglionblock in patients with complex regional pain syndrome.

Methods: Lumbar sympathetic ganglion block wasconducted in patients with lower-extremity complex regional pain syndrome using75 IU of botulinum toxin type A (botulinum toxin group) and local anesthetic(control group). The primary outcome was the change in the relative temperaturedifference on the blocked sole compared with the contralateral sole at 1postoperative month. The secondary outcomes were the 3-month changes inrelative temperature differences, as well as the pain intensity changes.

Results: A total of 48 participants (N = 24/group)were randomly assigned. The change in relative temperature increase was higherin the botulinum toxin group than in the control group (1.0°C ± 1.3 vs. 0.1°C ±0.8, respectively; difference: 0.9°C [95% CI, 0.3 to 1.5]; P = 0.006), whichwas maintained at 3 months (1.1°C ± 0.8 vs. -0.2°C ± 1.2, respectively; P =0.009). Moreover, pain intensity was greatly reduced in the botulinum toxingroup compared with the control group at 1 month (-2.2 ± 1.0 vs. -1.0 ± 1.6,respectively; P = 0.003) and 3 months (-2.0 ± 1.0 vs. -0.6 ± 1.6, respectively;P = 0.003). There were no severe adverse events pertinent to botulinum toxininjection.

Conclusions: In patients with complex regionalpain syndrome, lumbar sympathetic ganglion block using botulinum toxin type Aincreased the temperature of the affected foot for 3 months and also reducedthe pain.